IRON Dec 2024 40.000 call
- GlobeNewswire
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairsWATERTOWN, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Steve Caffé, MD as the company’s Chief Regulatory Officer
- GlobeNewswire
Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences: 2024 Wells Fargo Securities Healthcare Conference on Friday, September 6th at 10:15 a.m. ET.Morgan Stanley 22nd Annua
- Simply Wall St.
Here's Why We're Not Too Worried About Disc Medicine's (NASDAQ:IRON) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
